Use of pharmacotherapies for the management of addictive behaviours in Australian clinical practice

Addictive Behaviors

Volumn 31, Issue 11, 2006, Pages 1947-1958

  Doran, Christopher M ^a,b   Duszynski, Katherine M ^c   Beilby, Justin J ^c   Mattick, Richard P ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Alcohol; Australian general practice; Dependence; Nicotine; Pharmacotherapy

Indexed keywords

ACAMPROSATE; ALCOHOL; AMFEBUTAMONE; NALTREXONE; NICOTINE;

ADDICTION; ADULT; ALCOHOLISM; ARTICLE; AUSTRALIA; BEHAVIOR MODIFICATION; BEHAVIORAL SCIENCE; CLINICAL PRACTICE; COUNSELING; FEMALE; GASTROENTEROLOGY; GENERAL PRACTITIONER; HEALTH INSURANCE; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PRESCRIPTION; PSYCHIATRIST; QUESTIONNAIRE; SMOKING CESSATION PROGRAM; TOBACCO DEPENDENCE; TREATMENT OUTCOME; TREATMENT PLANNING;

ALCOHOL DETERRENTS; ALCOHOLISM; AUSTRALIA; BUPROPION; DOPAMINE UPTAKE INHIBITORS; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; NICOTINE; SUBSTANCE-RELATED DISORDERS; TAURINE; TOBACCO USE DISORDER;

EID: 33749682225     PISSN: 03064603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addbeh.2006.01.008     Document Type: Article

References (21)

1. Australian Institute of Health and Welfare. Australia's health 2002: The eighth biennial health report of the Australian Institute of Health and Welfare (2002), Australian Institute of Health and Welfare, Canberra
2. Bouza C., Magro A., Muñoz A., and Amate J.M. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction 99 (2004) 811-828
3. Britt H., Miller G.C., Know S., Charles J., Valenti L., Henderson J., et al. General practice activity in Australia 2002-2003 (2003), Australian Institute of Health and Welfare, Canberra (General Practice Series No. 14)
4. Collins D.J., and Lapsley H.M. Counting the cost: estimates of the social costs of drug abuse in Australia in 1998-99. National Drug Strategy Monograph Series No. 49 (2002), Commonwealth of Australia, Canberra
5. Commonwealth of Australia. Schedule of pharmaceutical benefits for approved pharmacists and medical practitioners (2005), Australian Government Publishing Service, Canberra
6. Gold P.B., Rubey R.N., and Harvey R.T. Naturalistic, self-assignment comparative trial of bupropion SR, a nicotine patch, or both for smoking cessation treatment in primary care. American Journal of Addiction 11 (2002) 315-331
7. Johnson C.D., Lucas L., and Uchishiba M.A. Efficacy and cost-effectiveness analysis of NRT patches vs. once-daily bupropion SR: A retrospective chart review. Journal of Pharmacy Technology 17 (2001) 140-146
8. Jorenby D.E. Smoking cessation strategies for the 21st century. American Heart Association 104 (2001) e51-e52
9. Kenna G.A., McGeary J.E., and Swift R.M. Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment: Part 1. American Journal of Health System Pharmacy 61 (2004) 2272-2279
10. Kenna G.A., McGeary J.E., and Swift R.M. Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment: Part 2. American Journal of Health System Pharmacy 61 (2004) 2380-2388
11. Kranzler H.R., and Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol, Clinical and Expiremental Research 25 (2001) 1335-1341
12. Mattick R.P., and Jarvis T.J. An outline for the management of alcohol problems: Quality assurance in the treatment of drug dependence project (1993), Australian Government Publishing Service, Canberra
13. MIMS Australia. MIMS annual 2005: Australian edition (2005), MIMS Australia, Sydney
14. Ministerial Council on Drug Strategy. National tobacco strategy, 2004-2009: The strategy (2004), Commonwealth of Australia, Canberra
15. National Preventive and Community Medicine Committee of The Royal Australian College of General Practitioners. Australian Family Physician 31 S1 (2002) 27-28
16. Ridolfo B., and Stevenson C. The quantification of drug-caused mortality and morbidity in Australia, 1998 (2001), Australian Institute of Health and Welfare, Canberra (Drug Statistics Series No. 7)
17. Shanahan M., Doran C.M., Gibson A., Stafford J., and Mattick R.P. Interventions for excessive alcohol use: Costs and outcomes of pharmacotherapies and other treatments (2005), National Drug and Alcohol Research Centre, University of New South Wales, Sydney
18. Stata Corporation. (2001). Stata statistical software, release 8.2. College Station: Stata Corporation.
19. The Tobacco Use and Dependence Guideline Panel SaCR. A clinical practice guideline for treating tobacco use and dependence. A US public health service report. Journal of American Medical Association 283 (2000) 3244-3254
20. Tønnesen P., Tonstad S., Hjalmarson A., Lebargy F., van Spiegel P.I., Hider A., et al. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. Journal of Internal Medicine 254 (2003) 184-192
21. Verheul R., Lehert P., Geerlings P.J., Koeter M.W., and van den Brink W. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology 178 (2005) 167-173